Treatment of mild–moderate calcified coronary lesions with sirolimus-eluting stent: real world data from a single center

    loading  Checking for direct PDF access through Ovid


BackgroundCalcified coronary lesions have commonly been considered as a challenge for interventional cardiologists, and few previous studies of sirolimus-eluting stent (SES) for calcified lesion have been limited by small sample size. Therefore, we evaluated the effectiveness of SES implantation for the treatment of calcified lesions in a large Chinese cohort of real world practice.MethodsA total of 956 consecutive patients who successfully received SES placement were enrolled in this study, and were divided into the two groups according to whether the mild–moderate calcified lesion treated with SES exists or not: noncalcified group (n = 637) and calcified group (n = 319). Lesions treated with SES were subjected to quantitative coronary angiography immediately and 8 months after stenting.ResultsBaseline characteristics including clinical, demographic or angiographic data were well balanced between the noncalcified and calcified groups. In the angiographic follow-up at 8 months, the in-stent restenosis and in-segment restenosis rates were similar in both the groups (in-stent restenosis: 3.8 vs. 4.0%, P>0.05; in-segment restenosis: 8.5 vs. 9.7%, P>0.05). The target lesion revascularization was not different between the two groups (5.2 vs. 6.8%; P>0.05). In addition, the in-stent late loss and overall thrombosis rate were also similar in both the groups (0.17±0.41 vs. 0.18±0.35 mm and 1.8 vs. 1.8%, P>0.05, respectively).ConclusionAlthough stenting of the calcified lesion was hard, successful treatment with SES for mild–moderate calcified lesions was conferred to similar favorable results compared with noncalcified lesions in patients with coronary artery disease.

    loading  Loading Related Articles